Novartis' MONALEESA-7 KISQALI (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
- KISQALI??is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.1
- At the time of the final overall survival analysis, median overall survival was not reached in the KISQALI??arm and was 40.9 months in the placebo arm.?The median duration of follow-up was 34.6 months.1
- Advanced breast cancer is the leading cause of cancer death in women 20-59 years old.2,3
KISQALI??is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. KISQALI??was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals. About Novartis in Advanced Breast Cancer
Novartis tackles breast cancer with advanced science, collaboration and a passion for transforming patient care. We've taken a bold approach to our research by including patient populations often neglected in clinical trials, identifying new pathways or mutations that may play a role in disease progression and developing therapies that not only maintain, but also improve, quality of life for patients. Our priority over the past 30 years and today is to deliver treatments proven to improve and extend lives for those diagnosed with advanced breast cancer. About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2019, the company invested?$51.8 million?in research and development in?Canada. Located in?Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1,000 people in?Canada?and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. For further information, please?consult?www.novartis.ca. About Novartis?
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at?www.novartis.com. KISQALI is a registered trademark. References
- KISQALI?, Product Monograph,?October 6, 2020. Available at:?www.novartis.ca/kisqalimonograph. Accessed on?October 28, 2020.
- Benz CC. Impact of aging on the biology of breast cancer.?Crit Rev Oncol Hematol. 2008;66:65-74.
- World Health Organization. Top cancer per country, estimated age-standardized mortality rates (world) in 2018, females, all ages. 2018. Available at:?http://gco.iarc.fr/today/home. ?Accessed on?October 28, 2020.
- Canadian Cancer Society. What is Metastatic Cancer? Available at:?http://www.cancer.ca/en/cancer-information/cancer-type/metastatic-cancer/metastatic-cancer/?region=on. Accessed on?October 28, 2020.
- Canadian Breast Cancer Network. What is Metastatic Breast Cancer? Available at:?https://www.cbcn.ca/en/what_is_mbc. Accessed on?October 28, 2020.
- Canadian Breast Cancer Network and Rethink Breast Cancer. Living with Metastatic Breast Cancer in?Canada. Available at:?https://www.cbcn.ca/web/default/files/public/Reports/Metastatic%20Breast%20Cancer%20In%20Canada%20Report%20June%202013%20-%20English.pdf. Accessed on?October 28, 2020.